Home › Compare › LVCLF vs QYLD

LVCLF vs QYLD: Dividend Comparison 2026

LVCLF yields 25316.46% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LVCLF wins by $545812235198788272128.00M in total portfolio value
10 years
LVCLF
LVCLF
● Live price
25316.46%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$545812235198788272128.00M
Annual income
$541,603,839,126,149,800,000,000,000.00
Full LVCLF calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — LVCLF vs QYLD

📍 LVCLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLVCLFQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LVCLF + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
LVCLF pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LVCLF
Annual income on $10K today (after 15% tax)
$2,151,898.73/yr
After 10yr DRIP, annual income (after tax)
$460,363,263,257,227,300,000,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, LVCLF beats the other by $460,363,263,257,227,300,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LVCLF + QYLD for your $10,000?

LVCLF: 50%QYLD: 50%
100% QYLD50/50100% LVCLF
Portfolio after 10yr
$272906117599394136064.00M
Annual income
$270,801,919,563,074,900,000,000,000.00/yr
Blended yield
99.23%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LVCLF buys
0
QYLD buys
0
No recent congressional trades found for LVCLF or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLVCLFQYLD
Forward yield25316.46% ✓11.92%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$545812235198788272128.00M ✓$25.4K
Annual income after 10y$541,603,839,126,149,800,000,000,000.00 ✓$5,659.31
Total dividends collected$545535052761023643648.00M ✓$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: LVCLF vs QYLD ($10,000, DRIP)

YearLVCLF PortfolioLVCLF Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$2,542,346$2,531,645.57$10,352$1,192.36+$2.53M → LVCLF
2$604,245,347$601,525,037.18$10,830$1,347.57+$604.23M → LVCLF
3$134,259,526,671$133,612,984,149.75$11,460$1,539.07+$134259.52M → LVCLF
4$27,889,421,383,128$27,745,763,689,589.74$12,275$1,777.84+$27889421.37M → LVCLF
5$5,416,349,539,098,672$5,386,507,858,218,725.00$13,323$2,078.95+$5416349539.09M → LVCLF
6$983,461,915,432,174,600$977,666,421,425,338,900.00$14,667$2,463.34+$983461915432.16M → LVCLF
7$166,956,658,621,138,240,000$165,904,354,371,625,800,000.00$16,396$2,960.57+$166956658621138.22M → LVCLF
8$26,500,723,640,478,440,000,000$26,322,080,015,753,820,000,000.00$18,631$3,612.97+$26500723640478440.00M → LVCLF
9$3,933,080,441,718,197,000,000,000$3,904,724,667,422,885,000,000,000.00$21,548$4,482.15+$3933080441718196736.00M → LVCLF
10$545,812,235,198,788,300,000,000,000$541,603,839,126,149,800,000,000,000.00$25,398$5,659.31+$545812235198788272128.00M → LVCLF

LVCLF vs QYLD: Complete Analysis 2026

LVCLF — Stock

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient for the of treatment for dementia, including Alzheimer's disease; NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient to treat cardiovascular disease, including hypertension. It is also developing AlgaraeOS in partnership with the University of New South Wales, an artificial intelligence platform for biopharmaceutical prediction of both fixed dose combination drug targets and repurposed drug targets agnostic to medical indication. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.

Full LVCLF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this LVCLF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LVCLF vs SCHDLVCLF vs JEPILVCLF vs OLVCLF vs KOLVCLF vs MAINLVCLF vs XYLDLVCLF vs JEPQLVCLF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.